Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
13F holders, Q2 2025
Institutional positions in Oculis Holding AG as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +3 vs. Q1 2025
- Shares held
- 5.11M
- +127.2K (+2.6%) vs. Q1 2025
- Total value
- $99.1M
- +$4.36M (+4.6%) vs. Q1 2025
- New holders
- 6
- 7 more added
- Sold out
- 3
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OCS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $322.0M |
| Q1 2026 | 57 | $534.7M |
| Q4 2025 | 41 | $363.8M |
| Q3 2025 | 20 | $191.7M |
| Q2 2025 | 23 | $99.1M |
| Q1 2025 | 20 | $94.7M |
| Q4 2024 | 12 | $59.4M |
| Q3 2024 | 10 | $36.9M |
| Q2 2024 | 11 | $39.8M |
| Q1 2024 | 9 | $40.9M |
| Q4 2023 | 7 | $44.3M |
| Q3 2023 | 9 | $32.1M |
| Q2 2023 | 9 | $38.5M |
| Q1 2023 | 7 | $23.2M |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Oculis Holding AG; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 2,300,774 | $44.7M | 27.68% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 1,253,119 | $24.3M | 0.04% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 514,702 | $9.99M | 15.75% | 00.0% | Unchanged |
| Sr One Capital Management, LP | 322,500 | $6.26M | 1.36% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 131,332 | $2.55M | 0.01% | 00.0% | Unchanged |
| UBS Group AG | 126,515 | $2.46M | 0.00% | +13,550+12.0% | Added |
| Acuta Capital Partners, LLC | 106,718 | $2.07M | 2.89% | −18,282−14.6% | Reduced |
| Compagnie Lombard Odier SCmA | 97,000 | $1.88M | 0.02% | +10,000+11.5% | Added |
| Woodline Partners LP | 50,568 | $981.5K | 0.01% | +50,568 | New |
| Bank of America Corp | 40,512 | $786.3K | 0.00% | +878+2.2% | Added |
| Geode Capital Management, LLC | 29,436 | $571.4K | 0.00% | +6,384+27.7% | Added |
| Northern Trust Corp | 23,319 | $452.6K | 0.00% | −513−2.2% | Reduced |
| Marshall Wace, LLP | 20,253 | $393.1K | 0.00% | +20,253 | New |
| Polen Capital Management LLC | 19,472 | $378.0K | 0.00% | +19,472 | New |
| Options Solutions, LLC | 19,472 | $378.0K | 0.14% | +19,472 | New |
| Kestra Private Wealth Services, LLC | 15,236 | $295.7K | 0.00% | +2,914+23.6% | Added |
| State Street Corp | 12,781 | $248.1K | 0.00% | +822+6.9% | Added |
| Morgan Stanley | 12,158 | $236.0K | 0.00% | +7,042+137.6% | Added |
| Bellevue Group AG | 9,700 | $188.3K | 0.00% | −4,400−31.2% | Reduced |
| Royal Bank of Canada | 45 | $1.00K | 0.00% | +45 | New |
| Raymond James Financial Inc | 26 | $505 | 0.00% | +26 | New |
| DuPont Capital Management Corp | 4 | $78 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 4 | $78 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −399−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −26−100.0% | Sold out |